The Immunosuppressive Metabolite of Leflunomide, A77 1726, Affects Murine T Cells Through Two Biochemical Mechanisms

Journal of Immunology

Volumn 159, Issue 1, 1997, Pages 22-27

  Elder, Robert T ^a   Xu, Xiulong ^a   Williams, James W ^a   Gong, Haihua ^a   Finnegan, Alison ^a   Chong, Anita S F ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; HYDROXYBUTYRIC ACID; IMMUNOSUPPRESSIVE AGENT; JAK1 PROTEIN, MOUSE; JAK3 PROTEIN, MOUSE; JANUS KINASE 1; JANUS KINASE 3; PROTEIN KINASE LCK; PROTEIN TYROSINE KINASE; TERIFLUNOMIDE;

ANIMAL; ARTICLE; CELL DIVISION; CELL LINE; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE;

ANILINE COMPOUNDS; ANIMALS; CELL DIVISION; CELL LINE; HYDROXYBUTYRATES; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASE 1; JANUS KINASE 3; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MICE; PROTEIN-TYROSINE KINASES; SRC-FAMILY KINASES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031179645     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bartlett, R. R., M. Dimitrijevic, and T. Mattar. 1991. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of auto immune disorders and reactions leading to transplantation rejection. Agents Actions 32:10.
2. Williams, J. W., F. Xiao, P. Foster, C. Clardy, L. McChesney, H. Sankary, and A. S.-F. Chong. 1994. Leflunomide in experimental transplantation: control of rejection and alooantibody production, reversal of acute rejection and interaction with cyclosporine. Transplantation 57:1223.
3. Xiao, F., A. S. Chong, P. Foster, H. Sankary, L. McChesney, G. Koukoulis, J. Yang, D. Frieders, and J. W. Williams. 1994. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 58:828.
4. Lin, Y., Sobis, M. Vandeputte, and M. Waer. 1995. Mechanism of leflunomide-induced prevention of xenoantibody formation and xenograft rejection in the hamster to rat heart transplantation model. Transplant. Proc. 27:305.
5. Xiao, F., A. Chong, J. Shen, J. Yang, J. Short, P. Foster, H. Sankary, S. Jensik, D. Mital, L. McChesney, G. Koukoulis, and J. W. Williams. 1995. Pharmacologically induced regression of chronic transplant rejection. Transplantation 60:1065.
6. Lin, Y., M. Vandeputte, and M. Waer. 1995. Effect of leflunomide and cyclosporine on the occurrence of chronic xenograft lesions. Kidney Int. 52(Suppl.):S23.
7. Mrowka, C., G. H. Thoenes, K. H. Langer, and R. R. Bartlett. 1994. Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide. Ann. Hematol. 68:195.
8. Williamson, R. A., C. M. Yea, P. A. Robson, A. P. Curnock, S. Gadher, A. B. Hambleton, K. Woodward, J.-M. Bruneay, P. Morand, O. Courtin, C. Sautes, R. Westwood, T. Hercend, E. A. Kuo, and E. Ruuth. 1995. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and a mediator of a range of biological effects of the immunomodulatory compound. J. Biol. Chem. 270:22467.
9. Bartlett, R. R., S. Popovic, and R. X. Raiss. 1988. Development of autoimmunity in MRL/lpr mice and the effects of drugs on this marine diseuses. Scand. J. Rheumatol. 75:S290.
10. Vivic-Dankovic, B., D. Kosec, M. Damjanovic, S. Apostolski, K. Isakovic, and R. R. Bartlett. 1995. Leflunomide prevents the development of experimentally induced myasthenis gravis. Int. J. Immunopharmacol. 17:273.
11. Chong, A. S.-F., J. Shen, F. Xiao, L. Blinder, L. Wei, H. Sankary, P. Foster, and J. Williams. 1996. Delayed xenograft rejection in the concordant hamster heart into Lewis rat model. Transplantation 62:90.
12. Lang, R., H. Wagner, and K. Heeg. 1995. Differential effects of the immunosuppressive agents cyclosporine and leflunomide in vivo. Transplantation 59:382.
13. Siemasko, K. F., A. S. F. Chong, J. W. Williams, E. G. Bremer, and A. Finnegan. 1996. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 61:635.
14. Mladenovic, V., Z. Domljan, B. Rozman, I. Jajic, D. Mihajlovic, J. Dordevic, M. Popovic, M. Dimitrijevic, M. Zivkovicx, G. Campion, P. Musikic, I. Low-Friedrich, C. Oed, H. Seifert, and V. Strand. 1995. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum. 38:1595.
15. Xu, X., J. W. Williams, E. Bremer, A. Finnegan, and A. S.-F. Chong. 1995. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem. 270:12398.
16. Mattar, T., K. Kochhar, R. Bartlett, H. G. Bremer, and A. Finnegan. 1993. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 334:161.
17. Xu, X., J. W. Williams, H. Gong, A. Finnegan, and A. S.-F. Chong. 1996. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726: inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem. Pharmacol. 52:527.
18. Greene, S., K. Watanabe, J. Braatz-Trulson, and L. Lou. 1995. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem. Pharmacol. 50:861.
19. Cherwinski, H. M., R. G. Cohn, P. Cheung, D. J. Webster, Y.-Z. Xu, J. P. Caulfield, J. M. Young, G. Nakano, and J. T. Ransom, 1995. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmcol. Exp. Ther. 275:1043.
20. Cherwinski, H. M., B. N., S. J. Ballaron, G. M. Nakano, J. M. Young, and J. T. Ransom. 1995. Leflunomide interferes with pyrimidine nucleotides biosynthesis. Inflamm. Res. 44:317.
21. Gillis, S., and K. A. Smith. 1977. Long-term culture of tumor-specific cytotoxic T cells. Nature 268:154.
22. lck deficiency on growth and cytolytic effector function of an interleukin-2-dependent cytotoxic T-cell line. Mol. Cell. Biol. 12:4521.
23. Malek, T. R., R. K. Furse, M. L. Fleming, A. J. Fadell, and Y.-W. He. 1995. Biochemical identity and characterization of the mouse interleukin-2 receptor β and γc subunits. J. Interferon Cytokine Res. 15:447.
24. Khym, J. X. 1977. An analytical system for rapid separation of tissue nucleotides at low pressures on conventional an ion exchangers. Clin. Chem. 21:1245.
25. Marth, J. D., R. Peet, E. G. Krebs, and R. M. Perlmutter. 1985. A lymphocyte-specific protein tyrosine kinase gene is rearranged and overexpressed in the murine T cell lymphoma LSTRA. Cell 43:393.
26. Kamps, M. P., and B. M. Sefton. 1989. Acid and base hydrolysis of phosphoproteins bound to Immobilon facilitates analysis of phosphoarnino acids in gelfractionated proteins. Anal. Biochem. 148:22.
27. Taniguchi, T. 1995. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 268:251.
28. Russell, S. M., J. A. Johnson, M. Noguchi, M. Kawamura, C. M. Bacon, M. Friedmann, M. Berg, D. W. McVicar, B. A. Witthuhn, O. Silvennoinen, A. S. Goldman, F. C. Schmalstieg, J. N. Ihle, J. J. O'Shea, and W. J. Leonard. 1994. Interaction of IL-2Rβ and γc chains with Jak1 and Jak3: implications for XSCID and SCID. Science 266:1042.
29. Levitzki, A., and A. Gazit. 1995. Tyrosine kinase inhibition: an approach to drug development. Science 267:1782.
30. Goldsmith, M. A., S. Y. Lai, W. Xu, M. C. Amaral, E. S. Kuczek, L. J. Parent, G. B. Mills, K. L. Tarr, G. D. Longmore, and W. C. Greene. 1995. Growth signal transauction by the human imerleukin-2 receptor requires cytoplasmic tyrosines of the β chain and non-tyrosine residues of the γc chain. J. Biol. Chem. 270:21729.
31. Karle, J. M., L. W. Anderson, D. D. Dietrick, and R. L. Cysk. 1980. Determination of serum and plasma uridine levels in mice, rats, and humans by high-pressure liquid Chromatography. Anal. Biochem. 109:41.
32. Lucien, J., V. C. Dias, D. F. LeGatt, and R. W. Yatscoff. 1995. Blood distribution and single-dose pharmacokinetics of leflunomide. Ther. Draft Monit. 17:454.
33. Webster, D. R., D. M. O. Becroft, and D. P. Suttle. 1995. Hereditary orotic aciduria and other disorders of pyrimidine metabolism. In The Metabolic and Molecular Bases of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Volle, eds. McGraw-Hill, Inc., New York, p. 1799.
34. Becroft, D. M. O., D. R. Webvster, H. A. Simmonds, L. D. Fairbanks, J. D. Wilson, and L. I. Phillips. 1986. Hereditary orotic aciduria: further biochemistry. Adv. Exp. Med. Biol. 195:67.
35. Becroft, D. M. O., L. I. Phillips, D. R. Webster, and J. D. Wilson. 1984. Absence of immune deficiency in hereditary orotic aciduria. N. Engl. J. Med. 310:1333.
36. Xu, X., L. Blinder, J. Shen, H. Gong, A. Finnegan, J. W. Williams, and A. S.-F. Chong. 1997. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J. Immunol. In press.